Skip to content
Aperlena
Language:

Estonia - Medicines - Procurement of biological medicinal products 2026

Original Eesti - Ravimid - Bioloogiliste ravimite hankimine 2026

Awarded Contract award No deadline published
Watch this tender

Bidding is closed. An award or a correction on this notice: an email when the register sees it. Log in

  1. Published
  2. Awarded pending

Summary

Machine-generated summary

The Estonian Health Insurance Fund, together with hospital partners, awarded a joint procurement of biological medicines. The products covered are biosimilar or bio-original medicines with active substances bevacizumab, nab-paclitaxel, tocilizumab, trastuzumab, rituximab and infliximab, including infusion concentrates, powder for infusion concentrate and solutions for injection in pen and syringe forms with various strengths. The contract was awarded to Farmatar OÜ with a value of EUR 10,381,903.05. Exclusion grounds and qualification conditions are set out in the procurement documents. Participating buyers include Ida-Tallinna Keskhaigla, Lääne-Tallinna Keskhaigla, Kuressaare Haigla, Põhja-Eesti Regionaalhaigla, Pärnu Haigla, Tallinna Lastehaigla and Tartu Ülikooli Kliinikum.

Description

Hanke objektiks on ravimid toimeainetega bevatsizumab, nab-paklitakseel, totsilizumab, trastuzumab, rituksimab ja infliksimab. Hankes osaleb Tervisekassa koos HVA haiglatega. / Kõrvaldamise alused ja kvalifitseerimistingimused: Vaata hanke alusdokumentidest L01FG01, Bevatsizumab, infusioonilahuse kontsentraat biosimilar või biooriginaal, 400 mg / Kõrvaldamise alused ja kvalifitseerimistingimused: Vaata hanke alusdokumentidest; L04AC07, Totsilizumab infusioonilahuse kontsentraat biosimilar või biooriginaal. Tugevused: 20 mg 1 ml 4 ml (80 mg); 20 mg 1 ml 10 ml (200 mg); 20 mg 1 ml 20 ml (400 mg) / Kõrvaldamise alused ja kvalifitseerimistingimused: Vaata hanke alusdokumentidest; L04AC07, Totsilizumab, süstelahus pen-süstlis, 162 mg 0,9 ml / Kõrvaldamise alused ja kvalifitseerimistingimused: Vaata hanke alusdokumentidest; L04AC07, Totsilizumab, süstelahus süstlis, 162 mg 0,9 ml / Kõrvaldamise alused ja kvalifitseerimistingimused: Vaata hanke alusdokumentidest; L04AB02, Infliksimab, infusioonilahuse kontsentraadi pulber või infusioonilahuse kontsentraat biosimilar või biooriginaal. Tugevus 100 mg või 100 mg ja 350 mg. / Kõrvaldamise alused ja kvalifitseerimistingimused: Vaata hanke alusdokumentidest

Official source

Source: TED - Tenders Electronic Daily (Publications Office of the EU)

Always verify details on the official notice.

Last verified against TED - Tenders Electronic Daily (Publications Office of the EU) 2 weeks ago

View the official notice

More from this buyer

Full buyer profile

Recent awards

Similar tenders

Market context

Avg. open tender · Medical equipment & pharmaceuticals
€9,651,178
11,136 open across Europe right now
Buyer track record on Aperlena
3 notices tracked · 3 awarded
€17,440,308 in awarded contracts

Never miss a tender like this

28 new notices in Medical equipment & pharmaceuticals in Estonia in the last 7 days. Get an email when new ones appear. Free.

Set up my alert
Source

Keyboard shortcuts

Read a list without reaching for the mouse. The shortcuts stay quiet while you type in a field.

j
Next result
k
Previous result
Enter
Open the result
n
Next page
p
Previous page
c
Compare this result
s
Shortlist this result
/
Jump to the search box
?
Show these shortcuts
Esc
Close